Estuary Biotherapeutics Raises $93 Million in Series A Funding
Estuary Biotherapeutics, a biotechnology firm dedicated to developing treatments for autosomal dominant polycystic kidney disease (ADPKD), has successfully raised $93 million in a Series A funding round. The Menlo Park, California-based company aims to advance genetic therapies for serious kidney diseases.
Investors and Leadership
The funding round was led by RA Capital Management, with participation from several notable investors including Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund, 4BIO Capital, and GV. Estuary Biotherapeutics was co-founded by a team with significant expertise in the field: Michael Caplan and Stefan Somlo serve as Scientific Co-Founders, while Wayne Sackett is the Co-Founder and CEO, and Xavier Anguela is also a Co-Founder.
Use of Funds
The newly secured funds will be directed towards advancing Estuary Biotherapeutics' pipeline of genetic medicines. The company is focused on addressing unmet needs in the treatment of kidney diseases, particularly ADPKD, a condition characterized by the growth of numerous cysts in the kidneys.
Looking Ahead
With this substantial financial backing, Estuary Biotherapeutics is well-positioned to continue its research and development efforts in the field of genetic therapies for kidney diseases. The involvement of prominent investors underscores the potential impact of their work in improving patient outcomes.